Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma: Myeloma
In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (Δ13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence in situ hybridization (iFISH) in a large multicenter study ( n =794). The ability to obtain...
Gespeichert in:
| Veröffentlicht in: | Leukemia 2006-09, Vol.20 (9), p.1610-1617 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1617 |
|---|---|
| container_issue | 9 |
| container_start_page | 1610 |
| container_title | Leukemia |
| container_volume | 20 |
| creator | Chiecchio, L Protheroe, R K M Ibrahim, A H Cheung, K L Rudduck, C Dagrada, G P Cabanas, E D Parker, T Nightingale, M Wechalekar, A Orchard, K H Harrison, C J Cross, N C P Morgan, G J Ross, F M |
| description | In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (Δ13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence
in situ
hybridization (iFISH) in a large multicenter study (
n
=794). The ability to obtain abnormal metaphases was associated with a poor prognosis, which was worse if Δ13, p53 deletion or t(4;14) was present, but only Δ13 remained significant on multivariate analysis. Patients with Δ13, by either cytogenetics or iFISH, had a poor prognosis. However, when cases with Δ13 detectable by both cytogenetics and iFISH were separated from those detected by iFISH only, the poor prognosis of iFISH-detectable Δ13 disappeared; their outcome matched that of patients with no detectable Δ13 (
P
=0.115). Addition of ploidy status to iFISH-Δ13 did not affect the prognostic value of the test. Indeed both cytogenetics and iFISH Δ13 divided both hyperdiploidy and nonhyperdiploidy into two groups with similar prognoses, indicating that the poor prognosis of ploidy is entirely due to its association with Δ13. We conclude that Δ13 detected by metaphase analysis is a critical prognostic factor in myeloma. Absence of Δ13, even in those patients yielding only normal or no metaphases, is associated with a relatively good prognosis. |
| doi_str_mv | 10.1038/sj.leu.2404304 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68778627</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188531320</galeid><sourcerecordid>A188531320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c582t-6e1ba576dcc7de29f5b130897ac12eebede86b5b67ae0e6366107cd29f4c43913</originalsourceid><addsrcrecordid>eNp1kk1v1DAQhi0EotvClSOyQPSWrb9ie49VoYBUiQucLceZ7CZy7GInSPvvcdRIW1ArH6zxPDPjmXkRekfJlhKur_Kw9TBvmSCCE_ECbahQsqrrmr5EG6K1quSOiTN0nvNAyOKUr9EZlZpJxvgGDZ_Bw9THgGOH3SHFMeY4AqYctzCBm6DFzRG7GP5AWDjrsTtOcQ-hhLmM-4wtdqkvRnHdp7gPMRcDd9ZNMeE-4PEIPo72DXrVWZ_h7XpfoF-3X37efKvufnz9fnN9V7las6mSQBtbK9k6p1pgu65uKCd6p6yjDKCBFrRs6kYqCwQkl5IS5doCCif4jvILdPmQt3zm9wx5MmOfHXhvA8Q5G6mV0pKpAn78DxzinEqH2TApakWUVKxQH56lGKmF0PxRqr31YPrQxSlZt9Q111TrmlPOSKG2T1DltDD2ZcTQ9eX9n4DLRwEHsH465OjnZRH5ycwuxZwTdOY-9aNNR0OJWYRi8mCKUMwqlBLwfu1qbkZoT_iqjAJ8WgGby2a7ZIPr84nTRErGl_FcPXC5uMIe0mk8z5T-C8Uc1Fs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220544837</pqid></control><display><type>article</type><title>Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma: Myeloma</title><source>MEDLINE</source><source>Nature Journals</source><source>EZB Electronic Journals Library</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chiecchio, L ; Protheroe, R K M ; Ibrahim, A H ; Cheung, K L ; Rudduck, C ; Dagrada, G P ; Cabanas, E D ; Parker, T ; Nightingale, M ; Wechalekar, A ; Orchard, K H ; Harrison, C J ; Cross, N C P ; Morgan, G J ; Ross, F M</creator><creatorcontrib>Chiecchio, L ; Protheroe, R K M ; Ibrahim, A H ; Cheung, K L ; Rudduck, C ; Dagrada, G P ; Cabanas, E D ; Parker, T ; Nightingale, M ; Wechalekar, A ; Orchard, K H ; Harrison, C J ; Cross, N C P ; Morgan, G J ; Ross, F M ; on behalf of the UK Myeloma Forum</creatorcontrib><description>In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (Δ13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence
in situ
hybridization (iFISH) in a large multicenter study (
n
=794). The ability to obtain abnormal metaphases was associated with a poor prognosis, which was worse if Δ13, p53 deletion or t(4;14) was present, but only Δ13 remained significant on multivariate analysis. Patients with Δ13, by either cytogenetics or iFISH, had a poor prognosis. However, when cases with Δ13 detectable by both cytogenetics and iFISH were separated from those detected by iFISH only, the poor prognosis of iFISH-detectable Δ13 disappeared; their outcome matched that of patients with no detectable Δ13 (
P
=0.115). Addition of ploidy status to iFISH-Δ13 did not affect the prognostic value of the test. Indeed both cytogenetics and iFISH Δ13 divided both hyperdiploidy and nonhyperdiploidy into two groups with similar prognoses, indicating that the poor prognosis of ploidy is entirely due to its association with Δ13. We conclude that Δ13 detected by metaphase analysis is a critical prognostic factor in myeloma. Absence of Δ13, even in those patients yielding only normal or no metaphases, is associated with a relatively good prognosis.</description><identifier>ISSN: 0887-6924</identifier><identifier>EISSN: 1476-5551</identifier><identifier>DOI: 10.1038/sj.leu.2404304</identifier><identifier>PMID: 16826223</identifier><identifier>CODEN: LEUKED</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Cancer Research ; Chromosome 13 ; Chromosome Deletion ; Chromosomes ; Chromosomes, Human, Pair 13 ; Cloning ; Cohort Studies ; Critical Care Medicine ; Cytogenetics ; Deletion ; Female ; Fluorescence ; Fluorescence in situ hybridization ; Genes, Immunoglobulin Heavy Chain ; Genes, p53 ; Genetic aspects ; Hematologic and hematopoietic diseases ; Hematology ; Humans ; Identification and classification ; Immunodeficiencies. Immunoglobulinopathies ; Immunoglobulinopathies ; Immunopathology ; In Situ Hybridization, Fluorescence ; Intensive ; Internal Medicine ; Leukemia ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Male ; Medical prognosis ; Medical research ; Medical sciences ; Medicine ; Medicine & Public Health ; Metaphase ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - genetics ; Multiple Myeloma - pathology ; Multivariate analysis ; Myeloma ; Oncology ; original-article ; Ploidies ; Ploidy ; Prognosis ; Survival Analysis ; Translocation, Genetic ; Tumors</subject><ispartof>Leukemia, 2006-09, Vol.20 (9), p.1610-1617</ispartof><rights>Springer Nature Limited 2006</rights><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Sep 2006</rights><rights>Nature Publishing Group 2006.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c582t-6e1ba576dcc7de29f5b130897ac12eebede86b5b67ae0e6366107cd29f4c43913</citedby><cites>FETCH-LOGICAL-c582t-6e1ba576dcc7de29f5b130897ac12eebede86b5b67ae0e6366107cd29f4c43913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.leu.2404304$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.leu.2404304$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18066232$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16826223$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiecchio, L</creatorcontrib><creatorcontrib>Protheroe, R K M</creatorcontrib><creatorcontrib>Ibrahim, A H</creatorcontrib><creatorcontrib>Cheung, K L</creatorcontrib><creatorcontrib>Rudduck, C</creatorcontrib><creatorcontrib>Dagrada, G P</creatorcontrib><creatorcontrib>Cabanas, E D</creatorcontrib><creatorcontrib>Parker, T</creatorcontrib><creatorcontrib>Nightingale, M</creatorcontrib><creatorcontrib>Wechalekar, A</creatorcontrib><creatorcontrib>Orchard, K H</creatorcontrib><creatorcontrib>Harrison, C J</creatorcontrib><creatorcontrib>Cross, N C P</creatorcontrib><creatorcontrib>Morgan, G J</creatorcontrib><creatorcontrib>Ross, F M</creatorcontrib><creatorcontrib>on behalf of the UK Myeloma Forum</creatorcontrib><title>Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma: Myeloma</title><title>Leukemia</title><addtitle>Leukemia</addtitle><addtitle>Leukemia</addtitle><description>In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (Δ13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence
in situ
hybridization (iFISH) in a large multicenter study (
n
=794). The ability to obtain abnormal metaphases was associated with a poor prognosis, which was worse if Δ13, p53 deletion or t(4;14) was present, but only Δ13 remained significant on multivariate analysis. Patients with Δ13, by either cytogenetics or iFISH, had a poor prognosis. However, when cases with Δ13 detectable by both cytogenetics and iFISH were separated from those detected by iFISH only, the poor prognosis of iFISH-detectable Δ13 disappeared; their outcome matched that of patients with no detectable Δ13 (
P
=0.115). Addition of ploidy status to iFISH-Δ13 did not affect the prognostic value of the test. Indeed both cytogenetics and iFISH Δ13 divided both hyperdiploidy and nonhyperdiploidy into two groups with similar prognoses, indicating that the poor prognosis of ploidy is entirely due to its association with Δ13. We conclude that Δ13 detected by metaphase analysis is a critical prognostic factor in myeloma. Absence of Δ13, even in those patients yielding only normal or no metaphases, is associated with a relatively good prognosis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Chromosome 13</subject><subject>Chromosome Deletion</subject><subject>Chromosomes</subject><subject>Chromosomes, Human, Pair 13</subject><subject>Cloning</subject><subject>Cohort Studies</subject><subject>Critical Care Medicine</subject><subject>Cytogenetics</subject><subject>Deletion</subject><subject>Female</subject><subject>Fluorescence</subject><subject>Fluorescence in situ hybridization</subject><subject>Genes, Immunoglobulin Heavy Chain</subject><subject>Genes, p53</subject><subject>Genetic aspects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematology</subject><subject>Humans</subject><subject>Identification and classification</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Intensive</subject><subject>Internal Medicine</subject><subject>Leukemia</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metaphase</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - pathology</subject><subject>Multivariate analysis</subject><subject>Myeloma</subject><subject>Oncology</subject><subject>original-article</subject><subject>Ploidies</subject><subject>Ploidy</subject><subject>Prognosis</subject><subject>Survival Analysis</subject><subject>Translocation, Genetic</subject><subject>Tumors</subject><issn>0887-6924</issn><issn>1476-5551</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kk1v1DAQhi0EotvClSOyQPSWrb9ie49VoYBUiQucLceZ7CZy7GInSPvvcdRIW1ArH6zxPDPjmXkRekfJlhKur_Kw9TBvmSCCE_ECbahQsqrrmr5EG6K1quSOiTN0nvNAyOKUr9EZlZpJxvgGDZ_Bw9THgGOH3SHFMeY4AqYctzCBm6DFzRG7GP5AWDjrsTtOcQ-hhLmM-4wtdqkvRnHdp7gPMRcDd9ZNMeE-4PEIPo72DXrVWZ_h7XpfoF-3X37efKvufnz9fnN9V7las6mSQBtbK9k6p1pgu65uKCd6p6yjDKCBFrRs6kYqCwQkl5IS5doCCif4jvILdPmQt3zm9wx5MmOfHXhvA8Q5G6mV0pKpAn78DxzinEqH2TApakWUVKxQH56lGKmF0PxRqr31YPrQxSlZt9Q111TrmlPOSKG2T1DltDD2ZcTQ9eX9n4DLRwEHsH465OjnZRH5ycwuxZwTdOY-9aNNR0OJWYRi8mCKUMwqlBLwfu1qbkZoT_iqjAJ8WgGby2a7ZIPr84nTRErGl_FcPXC5uMIe0mk8z5T-C8Uc1Fs</recordid><startdate>20060901</startdate><enddate>20060901</enddate><creator>Chiecchio, L</creator><creator>Protheroe, R K M</creator><creator>Ibrahim, A H</creator><creator>Cheung, K L</creator><creator>Rudduck, C</creator><creator>Dagrada, G P</creator><creator>Cabanas, E D</creator><creator>Parker, T</creator><creator>Nightingale, M</creator><creator>Wechalekar, A</creator><creator>Orchard, K H</creator><creator>Harrison, C J</creator><creator>Cross, N C P</creator><creator>Morgan, G J</creator><creator>Ross, F M</creator><general>Nature Publishing Group UK</general><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20060901</creationdate><title>Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma</title><author>Chiecchio, L ; Protheroe, R K M ; Ibrahim, A H ; Cheung, K L ; Rudduck, C ; Dagrada, G P ; Cabanas, E D ; Parker, T ; Nightingale, M ; Wechalekar, A ; Orchard, K H ; Harrison, C J ; Cross, N C P ; Morgan, G J ; Ross, F M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c582t-6e1ba576dcc7de29f5b130897ac12eebede86b5b67ae0e6366107cd29f4c43913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Chromosome 13</topic><topic>Chromosome Deletion</topic><topic>Chromosomes</topic><topic>Chromosomes, Human, Pair 13</topic><topic>Cloning</topic><topic>Cohort Studies</topic><topic>Critical Care Medicine</topic><topic>Cytogenetics</topic><topic>Deletion</topic><topic>Female</topic><topic>Fluorescence</topic><topic>Fluorescence in situ hybridization</topic><topic>Genes, Immunoglobulin Heavy Chain</topic><topic>Genes, p53</topic><topic>Genetic aspects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematology</topic><topic>Humans</topic><topic>Identification and classification</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Intensive</topic><topic>Internal Medicine</topic><topic>Leukemia</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metaphase</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - pathology</topic><topic>Multivariate analysis</topic><topic>Myeloma</topic><topic>Oncology</topic><topic>original-article</topic><topic>Ploidies</topic><topic>Ploidy</topic><topic>Prognosis</topic><topic>Survival Analysis</topic><topic>Translocation, Genetic</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiecchio, L</creatorcontrib><creatorcontrib>Protheroe, R K M</creatorcontrib><creatorcontrib>Ibrahim, A H</creatorcontrib><creatorcontrib>Cheung, K L</creatorcontrib><creatorcontrib>Rudduck, C</creatorcontrib><creatorcontrib>Dagrada, G P</creatorcontrib><creatorcontrib>Cabanas, E D</creatorcontrib><creatorcontrib>Parker, T</creatorcontrib><creatorcontrib>Nightingale, M</creatorcontrib><creatorcontrib>Wechalekar, A</creatorcontrib><creatorcontrib>Orchard, K H</creatorcontrib><creatorcontrib>Harrison, C J</creatorcontrib><creatorcontrib>Cross, N C P</creatorcontrib><creatorcontrib>Morgan, G J</creatorcontrib><creatorcontrib>Ross, F M</creatorcontrib><creatorcontrib>on behalf of the UK Myeloma Forum</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiecchio, L</au><au>Protheroe, R K M</au><au>Ibrahim, A H</au><au>Cheung, K L</au><au>Rudduck, C</au><au>Dagrada, G P</au><au>Cabanas, E D</au><au>Parker, T</au><au>Nightingale, M</au><au>Wechalekar, A</au><au>Orchard, K H</au><au>Harrison, C J</au><au>Cross, N C P</au><au>Morgan, G J</au><au>Ross, F M</au><aucorp>on behalf of the UK Myeloma Forum</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma: Myeloma</atitle><jtitle>Leukemia</jtitle><stitle>Leukemia</stitle><addtitle>Leukemia</addtitle><date>2006-09-01</date><risdate>2006</risdate><volume>20</volume><issue>9</issue><spage>1610</spage><epage>1617</epage><pages>1610-1617</pages><issn>0887-6924</issn><eissn>1476-5551</eissn><coden>LEUKED</coden><abstract>In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (Δ13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence
in situ
hybridization (iFISH) in a large multicenter study (
n
=794). The ability to obtain abnormal metaphases was associated with a poor prognosis, which was worse if Δ13, p53 deletion or t(4;14) was present, but only Δ13 remained significant on multivariate analysis. Patients with Δ13, by either cytogenetics or iFISH, had a poor prognosis. However, when cases with Δ13 detectable by both cytogenetics and iFISH were separated from those detected by iFISH only, the poor prognosis of iFISH-detectable Δ13 disappeared; their outcome matched that of patients with no detectable Δ13 (
P
=0.115). Addition of ploidy status to iFISH-Δ13 did not affect the prognostic value of the test. Indeed both cytogenetics and iFISH Δ13 divided both hyperdiploidy and nonhyperdiploidy into two groups with similar prognoses, indicating that the poor prognosis of ploidy is entirely due to its association with Δ13. We conclude that Δ13 detected by metaphase analysis is a critical prognostic factor in myeloma. Absence of Δ13, even in those patients yielding only normal or no metaphases, is associated with a relatively good prognosis.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>16826223</pmid><doi>10.1038/sj.leu.2404304</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-6924 |
| ispartof | Leukemia, 2006-09, Vol.20 (9), p.1610-1617 |
| issn | 0887-6924 1476-5551 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68778627 |
| source | MEDLINE; Nature Journals; EZB Electronic Journals Library; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Biological and medical sciences Cancer Research Chromosome 13 Chromosome Deletion Chromosomes Chromosomes, Human, Pair 13 Cloning Cohort Studies Critical Care Medicine Cytogenetics Deletion Female Fluorescence Fluorescence in situ hybridization Genes, Immunoglobulin Heavy Chain Genes, p53 Genetic aspects Hematologic and hematopoietic diseases Hematology Humans Identification and classification Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology In Situ Hybridization, Fluorescence Intensive Internal Medicine Leukemia Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical prognosis Medical research Medical sciences Medicine Medicine & Public Health Metaphase Middle Aged Multiple myeloma Multiple Myeloma - genetics Multiple Myeloma - pathology Multivariate analysis Myeloma Oncology original-article Ploidies Ploidy Prognosis Survival Analysis Translocation, Genetic Tumors |
| title | Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma: Myeloma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T21%3A16%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Deletion%20of%20chromosome%2013%20detected%20by%20conventional%20cytogenetics%20is%20a%20critical%20prognostic%20factor%20in%20myeloma:%20Myeloma&rft.jtitle=Leukemia&rft.au=Chiecchio,%20L&rft.aucorp=on%20behalf%20of%20the%20UK%20Myeloma%20Forum&rft.date=2006-09-01&rft.volume=20&rft.issue=9&rft.spage=1610&rft.epage=1617&rft.pages=1610-1617&rft.issn=0887-6924&rft.eissn=1476-5551&rft.coden=LEUKED&rft_id=info:doi/10.1038/sj.leu.2404304&rft_dat=%3Cgale_proqu%3EA188531320%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220544837&rft_id=info:pmid/16826223&rft_galeid=A188531320&rfr_iscdi=true |